<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">J Korean Med Sci</journal-id>
      <journal-id journal-id-type="publisher-id">JKMS</journal-id>
      <journal-title-group>
        <journal-title>Journal of Korean Medical Science</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1011-8934</issn>
      <issn pub-type="epub">1598-6357</issn>
      <publisher>
        <publisher-name>The Korean Academy of Medical Sciences</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">21655071</article-id>
      <article-id pub-id-type="pmc">3102879</article-id>
      <article-id pub-id-type="doi">10.3346/jkms.2011.26.6.824</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
          <subj-group>
            <subject>Oncology &amp; Hematology</subject>
          </subj-group>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Waldenstrom Macroglobulinemia with CD5+ Expression Presented as Cryoglobulinemic Glomerulonephropathy: A Case Report</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Kim</surname>
            <given-names>You Lim</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Gong</surname>
            <given-names>Soo Jung</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hwang</surname>
            <given-names>Young Hwan</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Joo</surname>
            <given-names>Jong Eun</given-names>
          </name>
          <xref ref-type="aff" rid="A2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Cho</surname>
            <given-names>Young Uk</given-names>
          </name>
          <xref ref-type="aff" rid="A3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lee</surname>
            <given-names>Jung Ae</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sung</surname>
            <given-names>Su Ah</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lee</surname>
            <given-names>So Young</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kim</surname>
            <given-names>Nae Yoo</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
      </contrib-group>
      <aff id="A1"><label>1</label>Department of Internal Medicine, Eulji University College of Medicine, Seoul, Korea.</aff>
      <aff id="A2"><label>2</label>Department of Pathology, Eulji University College of Medicine, Seoul, Korea.</aff>
      <aff id="A3"><label>3</label>Department of Laboratory Medicine, Eulji University College of Medicine, Seoul, Korea.</aff>
      <author-notes>
        <corresp>
Address for Correspondence: Soo Jung Gong, MD. Department of Internal Medicine, Eulji University College of Medicine, Eulji Medical Center, 14 Hangeulbiseok-gil, Nowon-gu, Seoul 139-872, Korea. Tel: +82.2-970-8206, Fax: +82.2-970-8621, <email>gsj1117@eulji.ac.kr</email></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <month>6</month>
        <year>2011</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>18</day>
        <month>5</month>
        <year>2011</year>
      </pub-date>
      <volume>26</volume>
      <issue>6</issue>
      <fpage>824</fpage>
      <lpage>828</lpage>
      <history>
        <date date-type="received">
          <day>11</day>
          <month>12</month>
          <year>2010</year>
        </date>
        <date date-type="accepted">
          <day>07</day>
          <month>3</month>
          <year>2011</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; 2011 The Korean Academy of Medical Sciences.</copyright-statement>
        <copyright-year>2011</copyright-year>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0">
          <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0">http://creativecommons.org/licenses/by-nc/3.0</ext-link>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Waldenstrom macroglobulinemia (WM) is a B-cell lymphoproliferative disorder associated with bone marrow involvement of lymphoplasmacytic lymphoma (LPL) and an IgM monoclonal gammopathy. Generally B-lymphocytes in LPL do not express CD5 that is important for differential diagnosis of B-cell lymphoproliferative disorders. In WM, various renal diseases and type I cryoglobulinemia are well described separately, but cryoglobulinemic glomerulonephropathy is very rarely reported. A 61-yr-old woman complained of generalized edema, cyanosis of the extremities in cold weather, visual disturbance, and pancytopenia. Bone marrow and renal biopsy showed CD5+ expressing B-cells and cryoglobulinemic glomerulonephropathy. With the diagnosis of WM, she received cyclophosphamide, doxorubicin, vincristine and prednisolone chemotherapy and got complete remission. Here, we report a rare case of WM associated with unusual expression of CD5+ B-lymphocytes and cryoglobulinemic glomerulonephropathy, and emphasize the importance of the clinical features in differentiating CD5+ B-cell lymphoproliferative disorders.</p>
      </abstract>
      <kwd-group>
        <kwd>Waldenstrom Macroglobulinemia</kwd>
        <kwd>CD5+ Lymphoplasmacytic Lymphoma</kwd>
        <kwd>Cryoglobulinemic Glomerulonephritis</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>INTRODUCTION</title>
      <p>Waldenstrom macroglobulinemia (WM) is a rare plasma cell disorder characterized by lymphoplasmacytic infiltration of bone marrow and by the demonstration of an IgM paraproteinemia (<xref ref-type="bibr" rid="B1">1</xref>). By the definition of the World Health Organization (WHO) and the Revised European-American Lymphoma (REAL) classification criteria, WM is classified as an indolent form of B-cell non-Hodgkin's lymphoma known as lymphoplasmacytic lymphoma (LPL) (<xref ref-type="bibr" rid="B2">2</xref>). LPL is a neoplasm of small B lymphocytes, plasmacytoid lymphocytes, and plasma cells, with variable numbers of immunoblasts (<xref ref-type="bibr" rid="B3">3</xref>). In LPL, small B lymphocytes are usually negative for CD5, CD10, and CD23, so LPL is presumed to derive from CD5 negative peripheral B lymphocytes stimulated to differentiate to plasma cells (<xref ref-type="bibr" rid="B4">4</xref>). In WM, only approximately 5%-20% of cases had CD5 positivity (<xref ref-type="bibr" rid="B5">5</xref>). The incidence of WM is not recognized in Asia, and LPL constitutes less than 5% of all non-Hodgkin lymphomas and is extremely rare in patients of East Asia (<xref ref-type="bibr" rid="B4">4</xref>). So the incidence of WM of CD5 positive LPL in Asia is guessed to be very uncommon.</p>
      <p>On the other hand, clinical features of WM are associated with tissue infiltration by neoplastic cells and IgM monoclonality (<xref ref-type="bibr" rid="B6">6</xref>). In WM, renal disease and type I cryoglobulinemia are well recognized, separately, but cryoglobulinemic glomerulonephropathy is very rare and only 2 cases have been reported worldwide (<xref ref-type="bibr" rid="B7">7</xref>, <xref ref-type="bibr" rid="B8">8</xref>).</p>
      <p>Now we report a rare case of WM associated with CD5+ LPL and presented as cryoglobulinemic glomerulonephropathy.</p>
    </sec>
    <sec sec-type="cases">
      <title>CASE DESCRIPTION</title>
      <p>On April 24, 2009, a 61-yr-old woman visited our hospital with generalized edema for 3 months. She also complained of tingling sensation and cyanosis of extremities in cold weather and visual disturbance. Physical examination showed mild anemic conjunctivae, splenomegaly and pretibial pitting edema on both legs. But there were no superficial lymph nodes and hepatomegaly. The laboratory findings revealed white blood cells, 3,270/&#xB5;L (segment neutrophil 57%; lymphocytes 28%); hemoglobin, 8.8 g/dL; and platelets, 81,000/&#xB5;L. Blood urea nitrogen, serum creatinine, total protein and albumin were 28.2 mg/dL, 1.4 mg/dL, 5.7 g/dL and 3.0 g/dL, respectively. In urinalysis, 4+ of proteinuria and 3+ of hematuria were found. Bence-Jones proteins were not found in urine. ANA was positive (1:640, speckled) and anti-ds DNA antibody was negative. The serum levels of IgG, IgA were normal (IgG, 972.47 mg/dL [normal 970-1,700 mg/dL], IgA, 242.07 mg/dL [normal 110-410 mg/dL]) but IgM was slightly elevated (246.41 mg/dL [normal 35-220 mg/dL]). C3 was 55.45 mg/dL (normal 86-160 mg/dL) and C4 was 1.6 mg/dL (normal 17-45 mg/dL). Serum LDH was 300 IU/L. HBsAg, anti-HBs and anti-HCV were all negative. In renal biopsy, we found that the glomeruli are generally enlarged showing marked endocapillary proliferation and irregularly thickened capillary wall with frequent obliteration of the capillary lumen due to pseudothrombi and subendothelial hyaline deposits with stained IgM. On the electron microscopic (EM) findings, there are subendothelial and mesangial electron dense deposits revealing microtubular structures compatible with cryoglobulinemic glomerulonephropathy (<xref ref-type="fig" rid="F1">Fig. 1</xref>). In additional tests, cryoglobulin was positive and the level of &#x3B2;2-microglobulin was 4.4 mg/L (normal 0-2.4 mg/L). Monoclonal gammopathy with IgM kappa type was seen in immunofixation electrophoresis (<xref ref-type="fig" rid="F2">Fig. 2A</xref>). Bone marrow biopsy revealed small lymphocytes with expression of CD5+CD20+ suggestive of B-cell lymphoproliferative disorders and positive reaction in small numbers of plasma cells with anti-cytoplasmic IgM antibody (<xref ref-type="fig" rid="F3">Fig. 3</xref>). Ophthalamic examination showed vascular segmentation and dilatation of the retinal veins (<xref ref-type="fig" rid="F4">Fig. 4</xref>) and PET-CT showed no abnormal hypermetabolic lesions. Thus, on the basis of symptoms, signs, the laboratory findings, renal biopsy and bone marrow examination, we diagnosed WM. She was treated with cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) chemotherapy. After the treatment, we observed negative proteinuria, hematuria, serum cryoglobulin and monoclonal gammopathy in immunofixation electrophoresis (<xref ref-type="fig" rid="F2">Fig. 2B</xref>). Complete blood cell profiles were normalized and lymphoid cell aggregation in bone marrow was absent. And she also had improved visual acuity and tingling sensation of upper and lower extremities.</p>
    </sec>
    <sec sec-type="discussion">
      <title>DISCUSSION</title>
      <p>According to the criteria of Waldenstrom Macroglobulinemia (WM) revised in the 4th edition of the WHO classification in 2008, the definition of WM combines the morphological diagnosis of bone marrow involvement of lymphoplasmacytic lymphoma (LPL) with IgM paraproteinemia (<xref ref-type="bibr" rid="B9">9</xref>). Owing to histological overlapping between lymphoplasmacytic lymphoma and other mature B-cell malignancies with plasmacytic differentiation, immunophenotyping is invaluable in the differential diagnosis of B-cell lymphoproliferative disorders, and in all cases of suspected WM it is needed to apply (<xref ref-type="bibr" rid="B5">5</xref>). The special immunophenotypic profile for lymphoplasmacytic cells in WM include the expression of monoclonal immunoglobulin light chain (&#x3BA; and &#x3BB; and the pan B-cell antigens CD19+CD20+ (<xref ref-type="bibr" rid="B1">1</xref>). The majority of cases have CD5-CD10-CD23-, but 5%-20% of patients appear to express the CD5 antigen (<xref ref-type="bibr" rid="B10">10</xref>). Although the expression of CD5+ in LPL/WM is uncommon, this should not preclude a diagnosis of WM. However, the attention should be paid to diagnose the CD5+ cases to exclude chronic lymphocytic leukemia and mantle cell lymphoma.</p>
      <p>In bone marrow examination of our patient, small lymphoid cells expressed CD5+CD20+ and positive reaction in small numbers of plasma cells with anti-cytoplasmic IgM antibody was observed. Because of CD5+ small lymphoid cells, the careful attention for symptoms and signs was important to differentiate from other B-cell lymphoproliferative disorders. Comparing to chronic lymphocytic leukemia, peripheral blood lymphocyte count of this patient was not compatible with the diagnostic criteria of the International Workshop on CLL (IW-CLL) (<xref ref-type="bibr" rid="B11">11</xref>). In mantle cell lymphoma, swelling of lymph nodes are usually present and gastrointestinal tract involvement occurs in a very high percentage and the majority of patients have genetic abnormalities such as t(11:14)(q13;q32) (<xref ref-type="bibr" rid="B3">3</xref>, <xref ref-type="bibr" rid="B12">12</xref>). This patient did not have lymphadenopathy and extranodal involvement in PET-CT and also did not have chromosome abnormalities. Instead of these characteristics of other B-cell lymphoproliferative disorders, this patient complained of hematuria, pretibial pitting edema, numbness of hand and foot in cold weather, and visual disturbance (<xref ref-type="bibr" rid="B13">13</xref>).</p>
      <p>Renal involvement of WM is a rare manifestation, but a wide spectrum of renal lesions is observed. After the first description of human renal lesions associated with deposition of monoclonal lights chains, several renal complications have been reported (<xref ref-type="bibr" rid="B7">7</xref>). WM-related nephropathies are characteristic intracapillary deposits of IgM. In renal biopsy of our patient, we found pseudothrombi and subendothelial hyaline deposits with stained IgM and subendothelial and mesangial electron dense deposits revealing microtubular structures on electron microscopy compatible with cryoglobulinemic nephropathy (<xref ref-type="bibr" rid="B14">14</xref>). Serum cryoglobulin of this patient was positive. Although there are a number of systemic conditions associated with cryoglobulinemia, including hepatitis C, lymphoproliferative disorders, infections, systemic lupus erythematosus (SLE) and other collagen vascular diseases, this patient was not associated with them. In WM, cryoglobulinemic glomerulonephropathy is a very rare renal disease which was reported in only 2 cases worldwide (<xref ref-type="bibr" rid="B7">7</xref>, <xref ref-type="bibr" rid="B8">8</xref>).</p>
      <p>In addition to renal disease, the patient complained of visual disturbance. Ophthalamic examination showed vascular segmentation and dilatation of the retinal veins. These revealed hyperviscosity syndrome (<xref ref-type="bibr" rid="B6">6</xref>). Hyperviscosity is a main feature in WM patients, and is due to the excess of IgM paraproteins. The relationship between serum viscosity and clinical manifestations is not precise, and a general absolute value for viscosity at which hyperviscosity becomes clinically relevant does not exist (<xref ref-type="bibr" rid="B15">15</xref>). And it is difficult to use commercial check of viscosity in Korea, so we couldn't run the tape over serum viscosity level.</p>
      <p>WM usually follows a relatively indolent course with a median survival ranging from 60 to 120 months in different series (<xref ref-type="bibr" rid="B16">16</xref>). However, in some patients the disease may be more aggressive (<xref ref-type="bibr" rid="B16">16</xref>). Several analyses have identified variables that may be associated with a worse prognosis. These include advanced age, cytopenia(s), hypoalbuminemia, elevated serum &#x3B2;2-microglobulin, high IgM, poor performance status, B-symptoms or splenomegaly. An International Prognositc Scoring System for WM (IPSSWM) was formulated based on 5 adverse covariates: age &gt; 65 yr, hemoglobin less than or equal to 11.5 g/dL, platelet count less than or equal to 100,000/&#xB5;L, &#x3B2;2-microglobulin more than 3 mg/L, and serum monoclonal protein concentration more than 7.0 g/dL. The risk group is categorized as having low, intermediate, high risk and five-year survival rates of these groups are 87%, 68%, and 36% respectively (<xref ref-type="bibr" rid="B17">17</xref>). Meanwhile, the indications for immediate therapy are disease-related cytopenias, bulky adenopathy or organomegaly, symptomatic hyperviscosity, severe neuropathy, amyloidosis, cryoglobulinemia, cold agglutinin disease, or evidence of disease transformation (<xref ref-type="bibr" rid="B13">13</xref>). There is no standard therapy for the treatment of symptomatic WM. Recent studies recommended the combination of rituximab with nucleoside analogs and/or alkylating agents or with cyclophosphamide-based therapies, or the combination of rituximab with thalidomide (<xref ref-type="bibr" rid="B13">13</xref>). An alternative frontline regimen can be considered along with bortezomib, alemtuzumab and stem cell transplantation. Newer agents, such as bendamustine and everolimus, can also be considered in the treatment of WM (<xref ref-type="bibr" rid="B6">6</xref>). According to IPSSWM, our patient is high risk group based on hemoglobin, platelet count and &#x3B2;2-microglobulin level. However, at present, no data suggest that new targeted therapies may overcome an adverse prognostic factor in WM and rituximab-based chemotherapy has economic problem in Korea. So we treated this patient with CHOP chemotherapy and after the treatment, the patient was in complete remission.</p>
      <p>In conclusion, WM associated with CD5+ LPL and presented as cryoglobulinemic glomerulonephropathy is very rare, so clinical features are important for differential diagnosis in CD5+ B-cell lymphoproliferative disorders. Conventional chemotherapy with CHOP is effective in symptomatic high risk group with cryoglobulinemia in WM.</p>
    </sec>
  </body>
  <back>
    <ref-list>
      <ref id="B1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Owen</surname>
              <given-names>RG</given-names>
            </name>
            <name>
              <surname>Treon</surname>
              <given-names>SP</given-names>
            </name>
            <name>
              <surname>Al-Katib</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Fonseca</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Greipp</surname>
              <given-names>PR</given-names>
            </name>
            <name>
              <surname>McMaster</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Morra</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Pangalis</surname>
              <given-names>GA</given-names>
            </name>
            <name>
              <surname>San Miguel</surname>
              <given-names>JF</given-names>
            </name>
            <name>
              <surname>Branagan</surname>
              <given-names>AR</given-names>
            </name>
            <name>
              <surname>Dimopoulos</surname>
              <given-names>MA</given-names>
            </name>
          </person-group>
          <article-title>Clinicopathological definition of Waldenstroms macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia</article-title>
          <source>Semin Oncol</source>
          <year>2003</year>
          <volume>30</volume>
          <fpage>110</fpage>
          <lpage>115</lpage>
          <pub-id pub-id-type="pmid">12720118</pub-id>
        </element-citation>
      </ref>
      <ref id="B2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Stone</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Pascual</surname>
              <given-names>V</given-names>
            </name>
          </person-group>
          <article-title>Pathophysiology of Waldenstr&#xF6;m's macroglobulinemia</article-title>
          <source>Haematologica</source>
          <year>2010</year>
          <volume>95</volume>
          <fpage>359</fpage>
          <lpage>364</lpage>
          <pub-id pub-id-type="pmid">20207842</pub-id>
        </element-citation>
      </ref>
      <ref id="B3">
        <label>3</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Fisher</surname>
              <given-names>RI</given-names>
            </name>
            <name>
              <surname>Mauch</surname>
              <given-names>PM</given-names>
            </name>
            <name>
              <surname>Harris</surname>
              <given-names>NL</given-names>
            </name>
            <name>
              <surname>Friedberg</surname>
              <given-names>JW</given-names>
            </name>
          </person-group>
          <person-group person-group-type="editor">
            <name>
              <surname>DeVita</surname>
              <given-names>VT</given-names>
              <suffix>Jr</suffix>
            </name>
            <name>
              <surname>Hellman</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Rosenberg</surname>
              <given-names>SA</given-names>
            </name>
          </person-group>
          <article-title>Non-Hodgkin's lymphoma</article-title>
          <source>Cancer: Principles and practice of oncology</source>
          <year>2005</year>
          <edition>7th ed</edition>
          <publisher-loc>Philadephia, PA</publisher-loc>
          <publisher-name>Lippincott Williams &amp; Wilkins</publisher-name>
          <fpage>1957</fpage>
          <lpage>1997</lpage>
        </element-citation>
      </ref>
      <ref id="B4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Won</surname>
              <given-names>YW</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Ko</surname>
              <given-names>YH</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>WS</given-names>
            </name>
          </person-group>
          <article-title>Clinical features and treatment outcomes of lymphoplasmacytic lymphoma: a single center experience in Korea</article-title>
          <source>Ann Hematol</source>
          <year>2010</year>
          <volume>89</volume>
          <fpage>1011</fpage>
          <lpage>1018</lpage>
          <pub-id pub-id-type="pmid">20449747</pub-id>
        </element-citation>
      </ref>
      <ref id="B5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Morice</surname>
              <given-names>WG</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Kurtin</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Hanson</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>McPhail</surname>
              <given-names>ED</given-names>
            </name>
          </person-group>
          <article-title>Novel immunophenotypic features of marrow lymphoplasmacytic lymphoma and correlation with Waldenstr&#xF6;m's macroglobulinemia</article-title>
          <source>Mod Pathol</source>
          <year>2009</year>
          <volume>22</volume>
          <fpage>807</fpage>
          <lpage>816</lpage>
          <pub-id pub-id-type="pmid">19287458</pub-id>
        </element-citation>
      </ref>
      <ref id="B6">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Treon</surname>
              <given-names>SP</given-names>
            </name>
          </person-group>
          <article-title>How I treat Waldenstr&#xF6;m macroglobulinemia</article-title>
          <source>Blood</source>
          <year>2009</year>
          <volume>114</volume>
          <fpage>2375</fpage>
          <lpage>2385</lpage>
          <pub-id pub-id-type="pmid">19617573</pub-id>
        </element-citation>
      </ref>
      <ref id="B7">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Audard</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Georges</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Vanhille</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Toly</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Deroure</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Fakhouri</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Cuvelier</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Belenfant</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Surin</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Aucouturier</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Mougenot</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Ronco</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Renal lesions associated with IgM-secreting monoclonal proliferations: revisiting the disease spectrum</article-title>
          <source>Clin J Am Soc Nephrol</source>
          <year>2008</year>
          <volume>3</volume>
          <fpage>1339</fpage>
          <lpage>1349</lpage>
          <pub-id pub-id-type="pmid">18632851</pub-id>
        </element-citation>
      </ref>
      <ref id="B8">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tomiyoshi</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Sakemi</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Yoshikawa</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Shimokama</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Watanabe</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Fibrillar crystal structure in essential monoclonal IgM kappa cryoglobulinemia</article-title>
          <source>Clin Nephrol</source>
          <year>1998</year>
          <volume>49</volume>
          <fpage>325</fpage>
          <lpage>327</lpage>
          <pub-id pub-id-type="pmid">9617499</pub-id>
        </element-citation>
      </ref>
      <ref id="B9">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ott</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Balague-Ponz</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>de Leval</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>de Jong</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Hasserjian</surname>
              <given-names>RP</given-names>
            </name>
            <name>
              <surname>Elenitoba-Johnson</surname>
              <given-names>KS</given-names>
            </name>
          </person-group>
          <article-title>Commentary on the WHO classification of tumors of lymphoid tissues (2008): indolent B cell lymphomas</article-title>
          <source>J Hematop</source>
          <year>2009</year>
          <volume>2</volume>
          <fpage>77</fpage>
          <lpage>81</lpage>
        </element-citation>
      </ref>
      <ref id="B10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Konoplev</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Medeiros</surname>
              <given-names>LJ</given-names>
            </name>
            <name>
              <surname>Bueso-Ramos</surname>
              <given-names>CE</given-names>
            </name>
            <name>
              <surname>Jorgensen</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Lin</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Immunophenotypic profile of lymphoplasmacytic lymphoma/Waldenstr&#xF6;m macroglobulinemia</article-title>
          <source>Am J Clin Pathol</source>
          <year>2005</year>
          <volume>124</volume>
          <fpage>414</fpage>
          <lpage>420</lpage>
          <pub-id pub-id-type="pmid">16191510</pub-id>
        </element-citation>
      </ref>
      <ref id="B11">
        <label>11</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hallek</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Cheson</surname>
              <given-names>BD</given-names>
            </name>
            <name>
              <surname>Catovsky</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Caligaris-Cappio</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Dighiero</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>D&#xF6;hner</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Hillmen</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Keating</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Montserrat</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Rai</surname>
              <given-names>KR</given-names>
            </name>
            <name>
              <surname>Kipps</surname>
              <given-names>TJ</given-names>
            </name>
          </person-group>
          <collab>International Workshop on Chronic Lymphocytic Leukemia</collab>
          <article-title>Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines</article-title>
          <source>Blood</source>
          <year>2008</year>
          <volume>111</volume>
          <fpage>5446</fpage>
          <lpage>5456</lpage>
          <pub-id pub-id-type="pmid">18216293</pub-id>
        </element-citation>
      </ref>
      <ref id="B12">
        <label>12</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ghielmini</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Zucca</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>How I treat mantle cell lymphoma</article-title>
          <source>Blood</source>
          <year>2009</year>
          <volume>114</volume>
          <fpage>1469</fpage>
          <lpage>1476</lpage>
          <pub-id pub-id-type="pmid">19556426</pub-id>
        </element-citation>
      </ref>
      <ref id="B13">
        <label>13</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dimopoulos</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Gertz</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Kastritis</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Garcia-Sanz</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Kimby</surname>
              <given-names>EK</given-names>
            </name>
            <name>
              <surname>LeBlond</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Fermand</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Merlini</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Morel</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Morra</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Ocio</surname>
              <given-names>EM</given-names>
            </name>
            <name>
              <surname>Owen</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Ghobrial</surname>
              <given-names>IM</given-names>
            </name>
            <name>
              <surname>Seymour</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Kyle</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Treon</surname>
              <given-names>SP</given-names>
            </name>
          </person-group>
          <article-title>Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia</article-title>
          <source>J Clin Oncol</source>
          <year>2009</year>
          <volume>27</volume>
          <fpage>120</fpage>
          <lpage>126</lpage>
          <pub-id pub-id-type="pmid">19047284</pub-id>
        </element-citation>
      </ref>
      <ref id="B14">
        <label>14</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Herrera</surname>
              <given-names>GA</given-names>
            </name>
            <name>
              <surname>Turbat-Herrera</surname>
              <given-names>EA</given-names>
            </name>
          </person-group>
          <article-title>Renal diseases with organized deposits: an algorithmic approach to classification and clinicopathologic diagnosis</article-title>
          <source>Arch Pathol Lab Med</source>
          <year>2010</year>
          <volume>134</volume>
          <fpage>512</fpage>
          <lpage>531</lpage>
          <pub-id pub-id-type="pmid">20367304</pub-id>
        </element-citation>
      </ref>
      <ref id="B15">
        <label>15</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vitolo</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Ferreri</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Montoto</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Lymphoplasmacytic lymphoma-Waldenstrom's macroglobulinemia</article-title>
          <source>Crit Rev Oncol Hematol</source>
          <year>2008</year>
          <volume>67</volume>
          <fpage>172</fpage>
          <lpage>185</lpage>
          <pub-id pub-id-type="pmid">18499469</pub-id>
        </element-citation>
      </ref>
      <ref id="B16">
        <label>16</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dimopoulos</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Kastritis</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Delimpassi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Zomas</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kyrtsonis</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Zervas</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>The International Prognostic Scoring System for Waldenstrom's macroglobulinemia is applicable in patients treated with rituximab-based regimens</article-title>
          <source>Haematologica</source>
          <year>2008</year>
          <volume>93</volume>
          <fpage>1420</fpage>
          <lpage>1422</lpage>
          <pub-id pub-id-type="pmid">18641029</pub-id>
        </element-citation>
      </ref>
      <ref id="B17">
        <label>17</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Morel</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Duhamel</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Gobbi</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Dimopoulos</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Dhodapkar</surname>
              <given-names>MV</given-names>
            </name>
            <name>
              <surname>McCoy</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Crowley</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Ocio</surname>
              <given-names>EM</given-names>
            </name>
            <name>
              <surname>Garcia-Sanz</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Treon</surname>
              <given-names>SP</given-names>
            </name>
            <name>
              <surname>Leblond</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Kyle</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Barlogie</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Merlini</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>International prognostic scoring system for Waldenstrom macroglobulinemia</article-title>
          <source>Blood</source>
          <year>2009</year>
          <volume>113</volume>
          <fpage>4163</fpage>
          <lpage>4170</lpage>
          <pub-id pub-id-type="pmid">19196866</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <floats-group>
    <fig id="F1" position="float">
      <label>Fig. 1</label>
      <caption>
        <p>Renal biopsy. (<bold>A</bold>) Immunofluorescent microscopic study showed 2+ reaction for IgM. (<bold>B</bold>) On the electron microscopic (EM) findings (&#xD7; 20,000), there are subendothelial (arrow) and mesangial electron dense deposits revealing microtubular structures (25 nm in average diameter).</p>
      </caption>
      <graphic xlink:href="jkms-26-824-g001"/>
    </fig>
    <fig id="F2" position="float">
      <label>Fig. 2</label>
      <caption>
        <p>Serum immunofixation electrophoresis. (<bold>A</bold>) There is a slightly dense band with IgM, kappa antisera, suggestive of monoclonal gammopathy (<bold>B</bold>) After the treatment, a dense band with IgM was disappeared.</p>
      </caption>
      <graphic xlink:href="jkms-26-824-g002"/>
    </fig>
    <fig id="F3" position="float">
      <label>Fig. 3</label>
      <caption>
        <p>Bone marrow biopsy. (<bold>A</bold>) Positive reaction in small lymphocytes with anti-CD5 antibody (immunohistochemical stain, &#xD7; 400). (<bold>B</bold>) Positive reaction in small numbers of plasma cells with anti-cytoplasmic IgM antibody (immunohistochemical stain, &#xD7; 400).</p>
      </caption>
      <graphic xlink:href="jkms-26-824-g003"/>
    </fig>
    <fig id="F4" position="float">
      <label>Fig. 4</label>
      <caption>
        <p>Ophthalmoscopic examination revealed dilatation and tortuosity of the retinal veins.</p>
      </caption>
      <graphic xlink:href="jkms-26-824-g004"/>
    </fig>
  </floats-group>
</article>
</pmc-articleset>
